Comparison of tumor mutation burden of 300 various non-Hodgkin lymphomas using panel based massively parallel sequencing
Abstract Background Tumor mutation burden is an emerging biomarker for immunotherapy. Although several clinical trials for immunotherapy in lymphoma have been carried out, the mutation burden of various lymphomas is not well known yet. Thus, the objective of this study was to compare tumor mutation...
Main Authors: | Junhun Cho, Sang Eun Yoon, Seok Jin Kim, Young Hyeh Ko, Won Seog Kim |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-08-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12885-021-08695-7 |
Similar Items
-
MASSIVE TUMOR BURDEN IN HODGKIN’S LYMPHOMA AS A PROGNOSTIC FACTOR IN YOUNG ADULTS
by: A. P. Karitsky
Published: (2016-02-01) -
Spatial Heterogeneity in Large Resected Diffuse Large B-Cell Lymphoma Bulks Analysed by Massively Parallel Sequencing of Multiple Synchronous Biopsies
by: Teresa Magnes, et al.
Published: (2021-02-01) -
Comprehensive analysis of clinical, pathological, and genomic characteristics of follicular helper T-cell derived lymphomas
by: Sang Eun Yoon, et al.
Published: (2021-05-01) -
EXPERIENCE IN THE TREATMENT OF REFRACTORY HODGKIN’S LYMPHOMA
by: A. M. Chervontseva, et al.
Published: (2021-03-01) -
Nivolumab in relapsed/refractory Hodgkin Lymphoma patients, single center experiences
by: Ramazan Acar, et al.
Published: (2020-12-01)